Ivermectin topical - Sanofi Pasteur

Drug Profile

Ivermectin topical - Sanofi Pasteur

Alternative Names: Sklice

Latest Information Update: 21 Aug 2012

Price : $50

At a glance

  • Originator Topaz Pharmaceuticals
  • Developer Sanofi Pasteur
  • Class Antiparasitics; Macrolides
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pediculosis

Most Recent Events

  • 21 Aug 2012 Launched for Pediculosis in USA (Topical) - First global launch
  • 07 Feb 2012 Registered for Pediculosis in USA (Topical) - First global approval
  • 07 Feb 2012 Final efficacy & adverse events data from the phase III LICE OUT trials in Pediculosis released by Sanofi Pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top